Topline results from the phase 3 DERBY and OAKS trials, released by Apellis Pharmaceuticals earlier this month, showed potential for pegcetacoplan to significantly reduce lesion growth in geographic atrophy.
“It is an extremely positive step forward. Pegcetacoplan may have the potential to become the first treatment available for this condition,” Frank G. Holz, MD, PhD, Euretina president, said at the virtual Euretina congress.
Pegcetacoplan is a C3 inhibitor designed to regulate overactivation of the complement cascade. The DERBY and OAKS trials investigated the safety and efficacy